Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aflibercept

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: Aflibercept. Displaying page 7 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2015-003723-65 Sponsor Protocol Number: MICM1014 Start Date*: 2016-01-12
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Aflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR)
    Medical condition: Retinitis Pigmentosa associated Cystoid Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002152-32 Sponsor Protocol Number: GR40306 Start Date*: 2019-04-30
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATIO...
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001441-14 Sponsor Protocol Number: IFOM-CPT002/2018/PO001 Start Date*: 2018-10-29
    Sponsor Name:IFOM - Istituto FIRC di Oncologia Molecolare - Milano
    Full Title: PEMBROLIZUMAB IN MMR-PROFICIENT METASTATIC COLORECTAL CANCER PHARMACOLOGICALLY PRIMED TO TRIGGER DYNAMIC HYPERMUTATION STATUS
    Medical condition: RAS mutated metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004042-42 Sponsor Protocol Number: GR40844 Start Date*: 2019-05-22
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATIO...
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PT (Completed) DE (Completed) HU (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000440-63 Sponsor Protocol Number: GR41984 Start Date*: 2020-09-30
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL ...
    Medical condition: Macular edema secondary to Branch Retinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PT (Completed) AT (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005104-10 Sponsor Protocol Number: GR40349 Start Date*: 2018-11-08
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA (YOSEMITE)
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) DE (Completed) HU (Completed) AT (Completed) PL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005105-12 Sponsor Protocol Number: GR40398 Start Date*: 2018-09-18
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH DIABETIC MACULAR EDEMA (RHINE)
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DK (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000621-39 Sponsor Protocol Number: Sym004-11 Start Date*: 2016-11-25
    Sponsor Name:Symphogen A/S
    Full Title: An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Ex...
    Medical condition: Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Doman of EGFR
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000642-35 Sponsor Protocol Number: HL217-201 Start Date*: 2019-09-19
    Sponsor Name:HANLIM PHARM CO., LTD
    Full Title: A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)
    Medical condition: AMD (age-related macular degeneration)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10068530 Macular degeneration progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005875-10 Sponsor Protocol Number: VGFTe-ROP-2036 Start Date*: 2022-03-10
    Sponsor Name:Regeneron Pharmaceuticals. Inc.
    Full Title: An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study
    Medical condition: Retinopathy of prematurity (ROP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003147-27 Sponsor Protocol Number: B1261009 Start Date*: 2014-01-10
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY 10017 US
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) WITH THAT OF ...
    Medical condition: PF-04634817 is a small molecule chemokine CCR2/5 receptor antagonist that is being developed for the treatment of diabetic nephropathy and diabetic macular edema.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10057934 Diabetic macular edema LLT
    18.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001221-40 Sponsor Protocol Number: 1336-0007 Start Date*: 2019-05-06
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Safety, tolerability and pharmacodynamics of single rising intravitreal and multiple rising intravitreal doses of BI 836880 in patients with wAMD (open label, non-randomized, uncontrolled).
    Medical condition: wet age-related macular degeneration (wAMD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    20.0 10015919 - Eye disorders 10075568 Wet age-related macular degeneration LLT
    20.0 10015919 - Eye disorders 10075718 Exudative age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004162-99 Sponsor Protocol Number: RAMTAS Start Date*: 2018-08-09
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: RAMTAS A Phase III study of RAMucirumab in combination with TAS102 vs. TAS102 monotherapy in chemotherapy refractory metastatic colorectal cancer patients
    Medical condition: Advanced metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002834-35 Sponsor Protocol Number: PARERE Start Date*: 2020-09-24
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients.
    Medical condition: RAS and BRAF wild-type chemorefractory metastatic colorectal cancer patients
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001096-20 Sponsor Protocol Number: UCL-mCRC-2018-MS100070-0095 Start Date*: 2018-08-03
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Avelumab combined with cetuximab and irinotecan for treatment refractory metastatic colorectal microsatellite stable cancer – A proof of concept, open label non-randomized Phase IIa study.
    Medical condition: TREATMENT FOR REFRACTORY METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000441-13 Sponsor Protocol Number: GR41986 Start Date*: 2020-08-27
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL ...
    Medical condition: Macular edema secondary to Central Retinal or Hemiretinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) AT (Completed) CZ (Completed) HU (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000257-39 Sponsor Protocol Number: PM60184-B-002-17 Start Date*: 2017-12-01
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Phase II, Open-label, Multicenter Study of PM060184 in Patients with Advanced Colorectal Cancer after Standard Treatment
    Medical condition: Advanced Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005655-16 Sponsor Protocol Number: Regard-CrC_2012 Start Date*: 2013-07-03
    Sponsor Name:Institut Jules Bordet
    Full Title: Regorafenib Assessment in Refractory advanced Colorectal cancer
    Medical condition: Advanced refractory colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002533-14 Sponsor Protocol Number: REVERT Start Date*: 2021-02-15
    Sponsor Name:DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
    Full Title: REVERT – taRgeted thErapy for adVanced colorEctal canceR paTients.
    Medical condition: unresectable metastatic colorectal cancer (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-006280-21 Sponsor Protocol Number: CORIOLAN Start Date*: 2012-04-27
    Sponsor Name:Jules Bordet Institute
    Full Title: Correlating the tumoral metabolic progression index measured by serial FDG PET-CT and apparent diffusion coefficient measured by MRI to patient's outcome in advance colorectal cancer
    Medical condition: Advanced colorectal cancer, refractory to all available medications
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 07:59:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA